The full Ready Inventory Clearance is now live. Rather than releasing the inventory a few products at a time, everything being cleared out is now available in one place. This allows you to see the entire list and combine anything you want into one order. Weekly Specials will continue and will be clearly marked in the order form as prices are reduced. Limited quantities • First come, first served • While supplies last. 👇 READY INVENTORY CLEARANCE ORDER FORM https://ezformz.net/f/dark-horse-ready-inventory-clearance-d3eys5

My daughter-in-law and the entire household just tested positive for COVID. Even the Frenchies! Kids are back in school. Summer vacations are over. Everyone is back into the daily grind—and apparently COVID got the memo. Halloween is next. Then Thanksgiving. Then Christmas. Then New Year's. They're all coming fast, and with them come family gatherings, travel, disrupted routines and a whole lot more exposure. So, its got me thinking: What’s your health plan for the next 90 days?

What's the Difference Between Cagrilintide and Eloralintide? Cagrilintide and Eloralintide are both long-acting amylin receptor agonists—peptides designed to mimic aspects of the natural hormone amylin to reduce appetite and increase satiety—but they differ significantly in their receptor selectivity and clinical development profiles. Receptor Selectivity Cagrilintide: Acts as a broader, non-selective amylin analogue. It activates multiple receptors across the amylin/calcitonin receptor family, including AMY1, AMY2, AMY3 and the calcitonin receptor. Eloralintide: Acts as a selective amylin receptor agonist developed by Eli Lilly. Rather than broadly activating the receptor family, Eloralintide preferentially targets the AMY1 receptor, with substantially greater activity at AMY1 than at the calcitonin receptor. That distinction—broad receptor activity versus preferential AMY1 activity—is one of the major reasons I find Eloralintide interesting. Clinical Trials and Administration Cagrilintide: Has been evaluated as a monotherapy and is also being developed in combination with other incretin-based therapies, most notably semaglutide as CagriSema. Cagrilintide broadly activates multiple amylin receptor complexes as well as the calcitonin receptor. Eloralintide: Has been evaluated as a once-weekly standalone subcutaneous injection, including a 48-week Phase 2 study that demonstrated substantial, dose-dependent reductions in body weight. Eloralintide is a highly selective amylin receptor agonist engineered by Eli Lilly to preferentially target the human AMY1 receptor rather than broadly activating the entire amylin/calcitonin receptor family. The theory behind that selectivity is particularly interesting: preserve strong amylin-mediated satiety signaling while potentially producing a different tolerability profile than broader amylin receptor activation. Side Effects Both Cagrilintide and Eloralintide influence appetite and satiety signaling, and gastrointestinal effects are prominent adverse events reported with this class.

I asked everyone what Dark Horse should investigate next. Looking back, I asked the wrong question. I don't need a list of subjects for me to research. We already have more research directions than we have time. What I'm interested in is what YOU are researching So, here's the question I should have asked: WHAT HAVE YOU BEEN DIGGING INTO? Bring to the community what you've actually been researching. Not simply a topic you'd like Dark Horse to research. Something you've been digging into yourself. Maybe it's a peptide, bioregulator, delivery method, pathway, study, protocol concept—or something completely outside the areas we've already discussed. What caught your attention? What have you learned so far? And what questions are you still trying to answer? You don't need to have it figured out. You don't need to write a research paper. And we certainly don't need to be experts. Just bring something to the table. We've covered a tremendous number of subjects. Some were intentionally high-level introductions—not deep dives—while others focused on going much deeper. Maybe one of them sent you down your own rabbit hole. If it did, tell us where it took you. I'd really like to see more people involved in the discussion and see us start learning from each other's research, rather than every conversation beginning with Dark Horse. So—what have YOU been digging into?

Back in January we discussed Thymalin, Thymogen and Thymulin. With fall approaching, there is a practical reason to bring them back into the conversation. Kids are back in school and bringing home whatever is circulating there. More people are returning to enclosed offices. Your train, subway or bus puts you in close proximity to people whose exposures you have absolutely no control over. Travel increases that circle even further. And as we move deeper into fall and winter, respiratory-virus season becomes part of the equation. So what are you actually trying to accomplish? Are you thinking PREVENTION and preparing for increased exposure? Then Thymogen may be the most logical of the three to research. It is the small, targeted Glu-Trp peptide associated with T-cell signaling, immune-response efficiency and regulation. Think of this less as rebuilding the immune system and more as supporting how an otherwise functioning immune system communicates and responds. Do you feel like your immune system needs more than a seasonal tune-up? Maybe you have been through illness, prolonged stress or another period that has taken something out of you. Thymalin is the broader approach. It is not a single peptide but a thymic peptide complex associated with T-cell maturation, CD4/CD8 balance and immune recovery. This is the one to research when the objective is less “prepare me for flu season” and more “rebuild the foundation before I get there.” Or is AGE part of the equation? That is where Thymulin becomes particularly interesting. Thymulin is a naturally occurring thymic hormone involved in T-cell differentiation and communication between the endocrine and immune systems. Its activity is zinc-dependent, and it declines significantly with age. So for an older researcher, the question may be different: am I trying to stimulate something, or am I interested in a thymic signal that naturally becomes weaker as we age? So going into fall, I would look at the three very simply: Increased seasonal exposure → look at Thymogen